In short
This article discusses a Phase II clinical trial investigating the use of ANV419, a fusion protein of IL-2 and humanized IgG1 monoclonal antibody against IL-2, in adoptive cell therapy for patients with advanced solid tumors. The study aims to compare ANV419 with high-dose IL-2 in terms of safety, efficacy, and patient-reported outcomes in the treatment of melanoma, non-small cell lung cancer, and cervical cancer.
At a glance
- Study Type
- Phase II randomized clinical trial
- Intervention
- ANV419 (IL-2 analog) vs. High-dose IL-2 in Adoptive Cell Therapy
- Target Conditions
- Advanced melanoma, non-small cell lung cancer (NSCLC), cervical cancer
- Primary Objectives
- Assess safety and patient-reported outcomes of ANV419 vs. high-dose IL-2
- Secondary Objectives
- Evaluate efficacy, quality of life, anxiety/depression, and health technology assessment
- Key Eligibility Criteria
- Adults with advanced solid tumors, adequate organ function, measurable disease
- Primary Endpoints
- Number of grade ≥3 adverse events, change in PRO-CTCAE composite score
- Secondary Endpoints
- Overall response rate, duration of response, progression-free survival, overall survival
What is ANV419?
ANV419 is an innovative drug being studied for cancer treatment. It is classified as a fusion protein, which means it combines two different proteins into one. Specifically, ANV419 is made up of: 1. Interleukin-2 (IL-2): A protein that helps stimulate the immune system 2. A humanized IgG1 monoclonal antibody against IL-2: An antibody designed to interact with IL-2 This unique combination is designed to enhance the body's natural ability to fight cancer.
How Does ANV419 Work?
ANV419 works by boosting the immune system's ability to recognize and attack cancer cells. The IL-2 component stimulates the growth and activity of certain immune cells, particularly T cells, which are crucial in fighting cancer. The antibody part of ANV419 is designed to modify how IL-2 interacts with the body, potentially improving its effectiveness and reducing side effects compared to using IL-2 alone.
Target Conditions
The clinical trial is focusing on patients with advanced solid tumors, specifically: Melanoma: A type of skin cancer Non-small cell lung cancer (NSCLC): The most common type of lung cancer Cervical cancer: Cancer that begins in the cervix These cancers have been chosen because they are known to respond to immunotherapy treatments.
Clinical Trial Overview
ANV419 is currently being studied in a Phase II clinical trial. This trial, called PragmaTIL, is comparing ANV419 to high-dose IL-2 in combination with a treatment called Tumor Infiltrating Lymphocytes (TIL) therapy. The main goals of the trial are: To see if ANV419 causes fewer severe side effects than high-dose IL-2 To evaluate how well patients tolerate the treatment To measure how effective ANV419 is in treating cancer To assess patients' quality of life during treatment Patients in the trial will receive either ANV419 or high-dose IL-2 after undergoing TIL therapy, which involves using a patient's own immune cells to fight their cancer.
Potential Benefits
Researchers hope that ANV419 will offer several advantages over current treatments: Fewer and less severe side effects compared to high-dose IL-2 Improved quality of life for patients during treatment Potentially better cancer-fighting ability Easier administration for patients and healthcare providers However, it's important to note that these potential benefits are still being studied and are not yet proven.
Safety and Side Effects
As with any new treatment, safety is a top priority in the ANV419 clinical trial. The researchers are closely monitoring for side effects, particularly those that might be related to stimulating the immune system. Some potential side effects being watched for include: Skin rash Fatigue Muscle pain Fever and chills Changes in blood pressure Breathing difficulties Changes in liver or kidney function The trial is designed to compare the side effects of ANV419 with those of high-dose IL-2, which is known to have significant side effects in some patients.
Patient Experience
The clinical trial is not only focused on the medical aspects of treatment but also on understanding the patient experience. Researchers are collecting information on: Quality of life during treatment Anxiety and depression levels Physical parameters like heart rate, mobility, and sleep patterns Patients' personal experiences and expectations through interviews This comprehensive approach aims to provide a fuller picture of how ANV419 affects patients' lives beyond just its medical effects.
Future Prospects
If ANV419 proves to be safe and effective in this clinical trial, it could potentially become a new option for treating certain types of advanced cancer. The researchers are also conducting economic analyses to understand the potential costs and benefits of ANV419 compared to current treatments. This information will be crucial in determining whether ANV419 could be widely adopted in healthcare systems.
It's important to remember that ANV419 is still in the research phase. While the results so far are promising enough to warrant this Phase II trial, more studies will be needed before it can be considered for approval as a standard treatment.